Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies
Charles F. Schuler, Carmen Gherasim, Kelly J. O’Shea, David M. Manthei, Jesse Chen, Cristyn Zettel, Jonathan P. Troost, Andrew A. Kennedy, Andrew W. Tai, Donald Giacherio, Riccardo Valdez, James L. Baldwin, James R. Baker
Abstract
This article demonstrates that people who have mild COVID-19 illnesses and produce antibodies are protected from reinfection for up to 6 months afterward. The antibodies that people produce in this situation are stable for up to 6 months as well. Clinical antibody assays correlate well with evidence of antibody-related viral neutralization activity.
Topics & Concepts
SeroconversionMedicineAntibodyVirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Neutralizing antibodyImmunologyImmunityVaccinationPersistence (discontinuity)Prospective cohort studyNeutralizationCoronavirus disease 2019 (COVID-19)Internal medicineDiseaseImmune systemInfectious disease (medical specialty)EngineeringGeotechnical engineeringSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing